Editas Medicine (EDIT) Competitors $1.03 -0.09 (-8.04%) Closing price 04:00 PM EasternExtended Trading$1.06 +0.02 (+2.43%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. ABVX, SNDL, VERV, ERAS, ORKA, RAPP, UPB, ETON, SANA, and PHATShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include ABIVAX Société Anonyme (ABVX), SNDL (SNDL), Verve Therapeutics (VERV), Erasca (ERAS), Oruka Therapeutics (ORKA), Rapport Therapeutics (RAPP), Upstream Bio (UPB), Eton Pharmaceuticals (ETON), Sana Biotechnology (SANA), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. ABIVAX Société Anonyme SNDL Verve Therapeutics Erasca Oruka Therapeutics Rapport Therapeutics Upstream Bio Eton Pharmaceuticals Sana Biotechnology Phathom Pharmaceuticals Editas Medicine (NASDAQ:EDIT) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Do insiders & institutionals have more ownership in EDIT or ABVX? 71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor EDIT or ABVX? In the previous week, Editas Medicine had 8 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 10 mentions for Editas Medicine and 2 mentions for ABIVAX Société Anonyme. Editas Medicine's average media sentiment score of 0.85 beat ABIVAX Société Anonyme's score of 0.01 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ABIVAX Société Anonyme 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, EDIT or ABVX? Editas Medicine has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. Do analysts rate EDIT or ABVX? Editas Medicine presently has a consensus target price of $6.83, suggesting a potential upside of 560.23%. ABIVAX Société Anonyme has a consensus target price of $38.00, suggesting a potential upside of 616.31%. Given ABIVAX Société Anonyme's stronger consensus rating and higher probable upside, analysts clearly believe ABIVAX Société Anonyme is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Editas Medicine 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07ABIVAX Société Anonyme 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is EDIT or ABVX more profitable? ABIVAX Société Anonyme has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. ABIVAX Société Anonyme's return on equity of 0.00% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Editas Medicine-340.96% -80.13% -50.99% ABIVAX Société Anonyme N/A N/A N/A Which has stronger valuation and earnings, EDIT or ABVX? Editas Medicine has higher revenue and earnings than ABIVAX Société Anonyme. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEditas Medicine$32.31M2.66-$153.22M-$2.88-0.36ABIVAX Société AnonymeN/AN/A-$159.90MN/AN/A Does the MarketBeat Community believe in EDIT or ABVX? Editas Medicine received 304 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 75.00% of users gave ABIVAX Société Anonyme an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote. CompanyUnderperformOutperformEditas MedicineOutperform Votes31353.23% Underperform Votes27546.77% ABIVAX Société AnonymeOutperform Votes975.00% Underperform Votes325.00% SummaryEditas Medicine and ABIVAX Société Anonyme tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.47M$2.83B$5.24B$7.07BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-0.4029.1621.1817.48Price / Sales2.64420.20356.3585.27Price / CashN/A168.6838.1634.64Price / Book0.243.486.233.79Net Income-$153.22M-$72.06M$3.20B$247.10M7 Day Performance-17.60%-12.92%-8.32%-7.32%1 Month Performance-41.48%-20.23%-3.36%-10.19%1 Year Performance-84.88%-34.36%2.72%-7.41% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine4.001 of 5 stars$1.03-8.0%$6.83+563.4%-83.7%$85.47M$32.31M-0.40230ABVXABIVAX Société Anonyme1.8361 of 5 stars$5.92-5.4%$38.00+542.4%-61.2%$375.42MN/A0.0061Gap DownSNDLSNDL3.4875 of 5 stars$1.43+1.1%$3.63+154.4%-43.2%$374.46M$920.45M-4.60580Positive NewsGap DownVERVVerve Therapeutics1.9088 of 5 stars$4.19-8.4%$25.50+509.3%-55.8%$370.72M$32.33M-1.70110News CoverageGap DownERASErasca3.5875 of 5 stars$1.25-9.1%$4.83+288.2%-44.2%$352.67MN/A-1.50120ORKAOruka TherapeuticsN/A$9.37-8.7%$39.86+325.4%N/A$350.79MN/A-1.50N/AGap DownRAPPRapport Therapeutics1.5594 of 5 stars$9.54-4.9%$35.00+266.9%N/A$348.17MN/A-0.69N/AShort Interest ↑Gap DownUPBUpstream BioN/A$6.52+6.6%$56.50+766.0%N/A$344.38M$2.37M0.0038Lockup ExpirationGap DownETONEton Pharmaceuticals2.716 of 5 stars$12.73-1.9%$27.67+117.3%+247.2%$340.99M$39.01M-57.8020Short Interest ↓Gap DownSANASana Biotechnology2.7932 of 5 stars$1.50-11.0%$10.80+622.4%-85.0%$336.86MN/A-1.07380PHATPhathom Pharmaceuticals3.1737 of 5 stars$4.86-22.6%$22.17+356.5%-49.2%$335.65M$55.25M-0.85110Analyst ForecastNews CoverageHigh Trading Volume Remove Ads Related Companies and Tools Related Companies ABIVAX Société Anonyme Competitors SNDL Competitors Verve Therapeutics Competitors Erasca Competitors Oruka Therapeutics Competitors Rapport Therapeutics Competitors Upstream Bio Competitors Eton Pharmaceuticals Competitors Sana Biotechnology Competitors Phathom Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDIT Stock Free EDIT Stock Alerts